Abstract:As the most common form of epigenetic regulation by RNA, N 6 methyladenosine (m 6 A) modification is closely involved in physiological processes, such as growth and development, stem cell renewal and differentiation, and DNA damage response. Meanwhile, its aberrant expression in cancer tissues promotes the development of malignant tumors, as well as plays important roles in proliferation, metastasis, drug resistance, immunity and prognosis. This close association between m 6 A and cancers has garnered substantial attention in recent years. An increasing number of small molecules have emerged as potential agents to target m 6 A regulators for cancer treatment. These molecules target the epigenetic level, enabling precise intervention in RNA modifications and efficiently disrupting the survival mechanisms of tumor cells, thus paving the way for novel approaches in cancer treatment. However, there is currently a lack of a comprehensive review on small molecules targeting m 6 A regulators for anti-tumor. Here, we have comprehensively summarized the classification and functions of m 6 A regulators, elucidating their interactions with the proliferation, metastasis, drug resistance, and immune responses in common cancers. Furthermore, we have provided a comprehensive overview on the development, mode of action, pharmacology and structure–activity relationships of small molecules targeting m 6 A regulators. Our aim is to offer insights for subsequent drug design and optimization, while also providing an outlook on future prospects for small molecule development targeting m 6 A.

Small Molecules that Regulate the N 6 -Methyladenosine RNA Modification as Potential Anti-Cancer Agents

The emerging roles of N6-methyladenosine RNA methylation in human cancers

Rna N-6-Methyladenosine Methylation In Post-Transcriptional Gene Expression Regulation

The Roles of M6a RNA Modifiers in Human Cancer

The Emerging Molecular Mechanism of M6a Modulators in Tumorigenesis and Cancer Progression

The roles of m<SUP>6</SUP>A RNA modifiers in human cancer

N6-methyladenosine modification: a novel pharmacological target for anti-cancer drug development

N<SUP>6</SUP>-methyladenosine as a biological and clinical determinant in colorectal cancer: progression and future direction

Methyladenosine Modification in RNAs: From Regulatory Roles to Therapeutic Implications in Cancer

N 6 ‐methyladenosine Steers RNA Metabolism and Regulation in Cancer

N6-methyladenosine Modification: an Important Player in the Tumor Immune Microenvironment.

RNA M6a Modification in Cancers: Molecular Mechanisms and Potential Clinical Applications.

Role of Main RNA Modifications in Cancer: N6-methyladenosine, 5-Methylcytosine, and Pseudouridine

Regulations of m6A and other RNA modifications and their roles in cancer

M6a Modification: a New Avenue for Anti-Cancer Therapy

N6-methyladenosine methyltransferases: functions, regulation, and clinical potential

The Roles of N6-methyladenosine and Its Target Regulatory Noncoding RNAs in Tumors: Classification, Mechanisms, and Potential Therapeutic Implications.

Role of N6-methyladenosine RNA modification in cancer

The potential role of RNA N6-methyladenosine in Cancer progression

Targeting RNA modifications with pharmacological agents: New frontiers in cancer therapy

Small molecule inhibitors targeting m6A regulators